1. |
GBD 2017 Causes of Death Collaborators. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet, 2018, 392(10159): 1736-1788.
|
2. |
Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2018, 68(6): 394-424.
|
3. |
Yang D, Liu Y, Bai C, et al. Epidemiology of lung cancer and lung cancer screening programs in China and the United States. Cancer Lett, 2020, 468: 82-87.
|
4. |
Ostrowski M, Marczyk M, Dziedzic R, et al. Lung cancer survival and comorbidities in lung cancer screening participants of the Gdansk screening cohort. Eur J Public Health, 2019, 29(6): 1114-1117.
|
5. |
Hirsch FR, Scagliotti GV, Mulshine JL, et al. Lung cancer: current therapies and new targeted treatments. Lancet, 2017, 389(10066): 299-311.
|
6. |
Detterbeck FC, Boffa DJ, Kim AW. The eighth edition lung cancer stage classification. Chest, 2017, 151(1): 193-203.
|
7. |
Wang J, Hui Z, Men Y, et al. Systemic inflammation-immune status predicts survival in stage III-N2 non-small cell lung cancer. Ann Thorac Surg, 2019, 108(6): 1701-1709.
|
8. |
Tong YS, Tan J, Zhou XL, et al. Systemic immune-inflammation index predicting chemoradiation resistance and poor outcome in patients with stage III non-small cell lung cancer. J Transl Med, 2017, 15(1): 221.
|
9. |
Qian S, Golubnitschaja O, Zhan X. Chronic inflammation: key player and biomarker-set to predict and prevent cancer development and progression based on individualized patient profiles. EPMA J, 2019, 10(4): 365-381.
|
10. |
Liu J, Li S, Zhang S, et al. Systemic immune-inflammation index, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio can predict clinical outcomes in patients with metastatic non-small-cell lung cancer treated with nivolumab. J Clin Lab Anal, 2019, 33(8): e22964.
|
11. |
Kumarasamy C, Sabarimurugan S, Madurantakam RM, et al. Prognostic significance of blood inflammatory biomarkers NLR, PLR, and LMR in cancer: a protocol for systematic review and meta-analysis. Medicine (Baltimore), 2019, 98(24): e14834.
|
12. |
Kiriu T, Yamamoto M, Nagano T, et al. The time-series behavior of neutrophil-to-lymphocyte ratio is useful as a predictive marker in non-small cell lung cancer. PLoS One, 2018, 13(2): e0193018.
|
13. |
World Health Organization. World Health Day 2012: ageing and health: toolkit for event organizers. Geneva: World Health Organization, 2012[2019-11-01]. https://apps.who.int/iris/handle/10665/70840.
|
14. |
王宏, 叶琴, 陆琳, 等. WS/T 405-2012血细胞分析参考区间. 中华检验医学杂志, 2015, 38(1): 62-63.
|
15. |
许春伟, 张博. WHO(2015)肺肿瘤组织学分类. 诊断病理学杂志, 2015, 22(12): 815-816.
|
16. |
Travis WD, Brambilla E, Nicholson AG, et al. The 2015 World Health Organization classification of lung tumors: impact of genetic, clinical and radiologic advances since the 2004 classification. J Thorac Oncol, 2015, 10(9): 1243-1260.
|
17. |
Suzuki R, Wei X, Allen PK, et al. Prognostic significance of total lymphocyte count, neutrophil-to-lymphocyte ratio, and platelet-to-lymphocyte ratio in limited-stage small-cell lung cancer. Clin Lung Cancer, 2019, 20(2): 117-123.
|
18. |
Liu D, Huang Y, Li L, et al. High neutrophil-to-lymphocyte ratios confer poor prognoses in patients with small cell lung cancer. BMC Cancer, 2017, 17(1): 882.
|
19. |
Zhang H, Zhang L, Zhu K, et al. Prognostic significance of combination of preoperative platelet count and neutrophil-lymphocyte ratio (COP-NLR) in patients with non-small cell lung cancer: based on a large cohort study. PLoS One, 2015, 10(5): e0126496.
|
20. |
张洁, 张小陆, 于杰, 等. 治疗前中性粒细胞与淋巴细胞比值对小细胞肺癌患者预后的意义. 河北医科大学学报, 2019, 40(3): 292-295.
|
21. |
王烨珣, 程淑霞. 220例肺癌患者外周血常规的变化及意义. 现代中西医结合杂志, 2012, 21(17): 1864-1865.
|
22. |
Schuller HM. The impact of smoking and the influence of other factors on lung cancer. Expert Rev Respir Med, 2019, 13(8): 761-769.
|
23. |
Bozinovski S, Vlahos R, Anthony D, et al. COPD and squamous cell lung cancer: aberrant inflammation and immunity is the common link. Br J Pharmacol, 2016, 173(4): 635-648.
|
24. |
付小芬, 熊小波. 血常规分析肺癌患者血细胞参数的变化及意义. 检验医学与临床, 2017, 14(2): 274-276.
|
25. |
孙舒岚, 李晓曦, 于志福, 等. 肺癌患者与健康人群血常规指标比较. 现代肿瘤医学, 2017, 25(8): 1237-1240.
|
26. |
Gomes M, Teixeira AL, Coelho A, et al. The role of inflammation in lung cancer. Adv Exp Med Biol, 2014, 816: 1-23.
|
27. |
Paliogiannis P, Fois AG, Sotgia S, et al. The neutrophil-to-lymphocyte ratio as a marker of chronic obstructive pulmonary disease and its exacerbations: a systematic review and meta-analysis. Eur J Clin Invest, 2018, 48(8): e12984.
|
28. |
Teng F, Ye H, Xue T. Predictive value of neutrophil to lymphocyte ratio in patients with acute exacerbation of chronic obstructive pulmonary disease. PLoS One, 2018, 13(9): e0204377.
|
29. |
Forget P, Machiels JP, Coulie PG, et al. Neutrophil: lymphocyte ratio and intraoperative use of ketorolac or diclofenac are prognostic factors in different cohorts of patients undergoing breast, lung, and kidney cancer surgery. Ann Surg Oncol, 2013, 20(Suppl 3): S650-S660.
|
30. |
Takada K, Kashiwagi S, Asano Y, et al. Clinical evaluation of dynamic monitoring of neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios in primary endocrine therapy for advanced breast cancer. Anticancer Res, 2019, 39(10): 5581-5588.
|
31. |
Yao CY, Liu XL, Tang Z. Prognostic role of neutrophil-lymphocyte ratio and platelet-lymphocyte ratio for hospital mortality in patients with AECOPD. Int J Chron Obstruct Pulmon Dis, 2017, 12: 2285-2290.
|
32. |
Stankovic B, Bjorhovde HAK, Skarshaug R, et al. Immune cell composition in human non-small cell lung cancer. Front Immunol, 2018, 9: 3101.
|